What transpired at the First Congress and Gathering of Nuclear Medicine, Hematology, Oncology, and Radiation Oncology Specialists?

On Thursday, 25/12/2025, in the conference hall of Shohada-e Tajrish Hospital, a group of cancer specialists gathered to exchange the latest scientific findings and share their experiences. This meeting, held under the title “The First Conference of Specialists in Nuclear Medicine, Radiation Oncology, Hematology, and Oncology,” featured specialists and researchers from various fields presenting their clinical experiences in dealing with cancer and reviewing novel methods for diagnosing and treating this disease.

Overall, this congress had five main sections: Diagnostic and Therapeutic Applications of FAPI, Diagnosis and Treatment of Prostate Cancer with PSMA PET/CT, Diagnosis and Treatment of Neuroendocrine Tumors, Novel Cancer Therapies using Alpha-Emitting Radionuclides, and Novel Therapies for Non-Melanoma Skin Cancer.

 

The first section began with a lecture by Professor Akbari, Head of the Cancer Research Center. Noting that the behavior of tumors and cancer cells is variable, he added: The use of FAPI as a novel method for high-precision cancer diagnosis and treatment can assist cancer surgeons and other specialists. Subsequently, Dr. Seyedeh Somayeh Banihashemian, a Fellow in Surgical Oncology, held a panel reviewing the diagnostic-therapeutic effect of Ga-68-FAPI and Lu-177-FAPI radiopharmaceuticals in patients with metastatic cancers. With the participation of several specialists from the fields of nuclear medicine, surgical oncology, hematology, and radiation oncology, and by reviewing several interesting treated cases, she effectively presented and evaluated the efficacy of these radiopharmaceuticals.

The second section, dedicated to the specialized prostate cancer panel, featured Dr. Emran Askari, a nuclear medicine specialist. Alongside several specialists in surgical oncology, hematology, oncology, radiation oncology, and urology, he addressed the application of PSMA PET/CT as a precise diagnostic tool for prostate cancer and introduced it as a practical method for selecting treatment stages.

Dr. Mahasti Amouei, a nuclear medicine specialist, together with several other specialists from the fields of nuclear medicine and radiation oncology, was able to thoroughly examine and analyze several cases diagnosed and treated with radiopharmaceuticals specific for neuroendocrine tumors.

Subsequently, Dr. Babak Fallahi, a nuclear medicine specialist, introduced alpha-emitting radiopharmaceuticals as a novel therapeutic tool in cancer treatment and presented radium-223 and actinium-225 radiopharmaceuticals by introducing their applications and effectiveness.

The final panel, dedicated to novel treatments for non-melanoma skin cancer, was held with two lectures. First, Dr. Nasrin Raeisi, a nuclear medicine specialist, introduced the Rhenium-188 topical cream and presented treated cases with it. She introduced Rhenium-188 cream as a novel treatment method worldwide, which, thanks to the efforts of Pars Isotope specialists as the second producer country globally, is now available in nuclear medicine centers for the treatment of non-melanoma skin cancer. In addition, Dr. Bita Fam, a researcher at the Skin Research Center of Shahid Beheshti University of Medical Sciences, described other novel methods for treating non-melanoma skin cancer.